GNH USA

Europe — EMA

Orgalutran (Ganirelix)

GNH ​

Request sourcing

1
Pack/s

What is Ganirelix?

Ganirelix, the active ingredient in Orgalutran, is a GnRH antagonist presented as a 250 µg/0.5 mL injection solution for subcutaneous use. It is used to prevent premature luteinizing hormone surges during controlled ovarian hyperstimulation in assisted reproductive technology cycles for women undergoing IVF or ICSI. GNH USA supplies Orgalutran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Orgalutran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Ganirelix used for?

Orgalutran is a GnRH antagonist used in fertility treatment protocols that control ovarian stimulation.

- Prevention of premature LH surge: Helps maintain timing of ovulation during IVF/ICSI cycles. - Controlled ovarian hyperstimulation: Allows precise dosing of gonadotropins by preventing early luteinization. - Assisted reproductive technology cycles: Supports the overall success of IVF and ICSI procedures.

What are the side effects of Ganirelix?

Ganirelix is generally well tolerated, but injection site reactions and hormonal changes can occur.

Common Side Effects: - Injection site pain or erythema: Mild discomfort at the injection site. - Headache: Transient headache without other neurological signs. - Nausea: Mild, self‑limiting nausea. - Fatigue: General tiredness that resolves spontaneously. - Abdominal discomfort: Mild cramping or bloating.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): Severe fluid shift requiring medical attention. - Allergic reaction: Rash, itching, swelling, or anaphylaxis. - Severe abdominal pain: May indicate complications such as ovarian torsion. - Thromboembolic events: Unusual clot formation. - Hypersensitivity: Systemic signs of a severe allergic response.

What precautions apply to Ganirelix?

When using Orgalutran, careful monitoring and adherence to clinical guidelines are essential.

- Patient selection: Confirm indication for assisted reproductive technology and assess baseline ovarian reserve. - Monitoring: Perform regular ultrasound and hormone assessments during stimulation. - Contraindications: Do not use in women with known hypersensitivity to ganirelix or any excipients. - Pregnancy status: Avoid use in confirmed pregnancy; the drug is intended for use before ovulation. - Drug interactions: Review concomitant medications that may affect hormonal balance. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake the vial.

What does Ganirelix interact with?

Ganireblox may interact with other hormonal agents used in fertility protocols; awareness of these interactions helps maintain treatment efficacy.

Major Interactions (Avoid): - GnRH agonists: Concurrent use can negate antagonist effect. - High‑dose estrogen therapy: May alter hormonal feedback mechanisms.

Moderate Interactions (Monitor Closely): - Anticoagulants: Monitor coagulation parameters if patient is on blood thinners. - Corticosteroids: May require dose adjustment of gonadotropins. - Antihistamines: May mask early signs of an allergic reaction. - CYP450 inducers: Potentially reduce plasma levels of ganache. - Herbal supplements: St. St  

Frequently asked questions

  +
  
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Product details

Drug
Ganirelix
Route
Subcutaneous Use
Manufacturer
N.V. Organon
Origin
EU

Related products